Home › Modalities › Peptide

Peptide (21 companies)

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
AKTS Aktis Oncology Oncology 8 Phase 1 $910M 10
ALT Altimmune GI/HepatologyMetabolic+1 3 Phase 3 $298M 3
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 3 Phase 3 $3.54B 5
BCYC Bicycle Therapeutics Oncology 3 Phase 2 $224M 4
ELTX Elicio Therapeutics Oncology 5 Phase 2 $40.5M 6
ENTX Entera Bio GI/HepatologyMetabolic Rare 4 Phase 2 $522M 4
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 1 Approved $1.84B 17
GLSI Greenwich LifeSciences Oncology 1 Phase 3 $274M 1
KAPA Kairos Pharma Oncology 1 Phase 2 $1.9M 12
KZIA Kazia Therapeutics NeurologyOncology Rare 4 Phase 2 $60.7M 13
MBX MBX Biosciences Metabolic Rare 4 Phase 3 $2.64B 4
NGEN NervGen Pharma Neurology 2 Phase 3 $211M 3
PTN Palatin Technologies ImmunologyMetabolic+1 5 Phase 3 $9.5M 5
PMN ProMIS Neurosciences Neurology Rare 3 Phase 1 $28.9M 9
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 10 Approved $8.14B 12
RNTX Rein Therapeutics Respiratory Rare 1 Phase 2 $30.7M 1
RYTM Rhythm Pharmaceuticals Metabolic Rare 12 Approved $8.08B 14
SLS SELLAS Life Sciences Group Oncology 5 Phase 3 $3.90B 9
VRCA Verrica Pharmaceuticals DermatologyOncology Rare 2 Approved $53.9M 4
VKTX Viking Therapeutics MetabolicNeurology Rare 4 Phase 3 $3.43B 9
XERS Xeris Biopharma MetabolicNeurology Rare 1 Approved $3.07B 4